ArticleJournal of medicinal chemistry2026
Development of a Direct-to-Biology Platform to Discover Potent MNK Inhibitors.
Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Accelerate Your Science: Direct-to-Biology Strategies in Medicinal Chemistry.Journal of medicinal chemistry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Eukaryotic translation initiation factor 4E (eIF4E) plays an essential role in driving the translation of mRNAs that promote cell proliferation. Its activity is regulated through phosphorylation at Ser209 by MNK1/2 kinases, which are downstream effectors of mitogen-activated protein kinase signaling. Elevated eIF4E phosphorylation drives malignant progression in multiple cancers, including glioblastoma, where it promotes translation of key oncoproteins responsible for tumor growth and therapy resistance. Here, we report the development and application of a direct-to-biology (D2B) platform to rapidly optimize new MNK inhibitors for cellular inhibition. This approach combines plate-based library synthesis with an in-cell Western assay to efficiently generate structure-activity relationship (SAR) data and new compounds with potent cellular inhibition. Using this platform, we synthesized and tested >150 new analogs directly in cells, identifying inhibitors with IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.